English

Eligibility Criteria

5 forms  
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
The presence of the EML4-ALK fusion protein was confirmed by RT-PCR for all patient-derived tumors before sequencing. Tumor specimens included in the treatment-naive cohort were obtained before treatment was initiated. Tumor specimens included in the crizotinib-resistant cohort were obtained after the development of resistance to crizotinib following an initial response to crizotinib.
Description

Elig.phs000855.v1.p1.1

Data type

boolean

Alias
UMLS CUI [1,1]
C3499377
UMLS CUI [1,2]
C0750484
UMLS CUI [1,3]
C0599161
UMLS CUI [2,1]
C0200345
UMLS CUI [2,2]
C0332152
UMLS CUI [2,3]
C0087111
UMLS CUI [3,1]
C0200345
UMLS CUI [3,2]
C0231290
UMLS CUI [3,3]
C2974289
UMLS CUI [3,4]
C1514892
Back to the top of the page

Similar models

Eligibility Criteria

5 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs000855.v1.p1.1
Item
The presence of the EML4-ALK fusion protein was confirmed by RT-PCR for all patient-derived tumors before sequencing. Tumor specimens included in the treatment-naive cohort were obtained before treatment was initiated. Tumor specimens included in the crizotinib-resistant cohort were obtained after the development of resistance to crizotinib following an initial response to crizotinib.
boolean
C3499377 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
C0599161 (UMLS CUI [1,3])
C0200345 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C0200345 (UMLS CUI [3,1])
C0231290 (UMLS CUI [3,2])
C2974289 (UMLS CUI [3,3])
C1514892 (UMLS CUI [3,4])
Back to the top of the page